Metformin monotherapy

Metformin monotherapy has been studied in 1 paper since 2024: 1 observational study in people. The newest paper, Dec 21, 2024: “Positive impact of DPP-4 or SGLT2 inhibitors on mild cognitive impairment in type 2 diabetes patients on metformin therapy: A metabolomic mechanistic insight”.

Exposure

1 paper studies it1 findingUpdated

See all 1 papers on metformin monotherapy

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“T2D patients on metformin monotherapy exhibited enriched purine, glutathione and sphingolipid metabolism”
Positive impact of DPP-4 or SGLT2 inhibitors on mild cognitive impairment in type 2 diabetes patients on metformin therapy: A metabolomic mechanistic insightBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2024doi:10.1016/j.biopha.2024.117771
Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Funders: CH Foundation and 1 more
  • Humans1

What did studies of metformin monotherapy find?

1

Studies of metformin monotherapy measured one outcome, purine metabolism.

Purine metabolism

upin humans1

1 study
  1. Metformin monotherapy is linked with higher purine metabolism in humans.

    “T2D patients on metformin monotherapy exhibited enriched purine, glutathione and sphingolipid metabolism”

    Humansserum

    Positive impact of DPP-4 or SGLT2 inhibitors on mild cognitive impairment in type 2 diabetes patients on metformin therapy: A metabolomic mechanistic insight

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

More on Purine metabolism

Latest